Premium
Rasagiline shows promise in treating negative symptoms of schizophrenia
Publication year - 2015
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30050
Subject(s) - rasagiline , schizophrenia (object oriented programming) , monoamine oxidase inhibitor , psychiatry , medicine , monoamine oxidase , pharmacology , psychology , parkinson's disease , chemistry , disease , biochemistry , enzyme
Results of a new study involving 60 patients with schizophrenia support additional research into the potential benefits of the monoamine oxidase inhibitor (MAOI) rasagiline in addressing troubling negative symptoms of the illness. The most pronounced effect seen from rasagiline was on avolition, a lack of drive to pursue goals that is highly associated with functional impairment in patients with schizophrenia. Study results were published online Nov. 2, 2014, in Schizophrenia Bulletin .